Mouse Anti-MLLT1 Recombinant Antibody (CBFYE-1554) (CBMAB-E2202-FY)

Raux, B., Buchan, K. A., Bennett, J., Christott, T., Dowling, M. S., Farnie, G., ... & Londregan, A. T. (2024). Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3. Bioorganic & Medicinal Chemistry Letters, 98, 129546.

Tan, L., Wang, L., Liu, J., & Yu, Y. (2023). Circvrk1 downregulation attenuates brain microvascular endothelial cell damage induced by oxygen–glucose deprivation through modulating the miR-150-5p/MLLT1 axis. Experimental Brain Research, 241(3), 781-791.

Yu, N., Tian, W., Liu, C., Zhang, P., Zhao, Y., Nan, C., ... & Liu, Y. (2023). miR-122-5p Promotes Peripheral and Central Nervous System Inflammation in a Mouse Model of Intracerebral Hemorrhage via Disruption of the MLLT1/PI3K/AKT Signaling. Neurochemical Research, 48(12), 3665-3682.

Kabra, A., & Bushweller, J. (2022). The intrinsically disordered proteins MLLT3 (AF9) and MLLT1 (ENL)–multimodal transcriptional switches with roles in normal hematopoiesis, MLL fusion leukemia, and kidney cancer. Journal of Molecular Biology, 434(1), 167117.

Liu, C., Li, X., Xiong, F., Wang, L., Chen, K., Wu, P., & Zhang, Z. (2022). Down-regulation of MLLT1 super elongation complex subunit impairs the anti-tumor activity of natural killer cells in esophageal cancer. Immunobiology, 227(4), 152238.

Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Felsani, A., ... & Cenciarelli, C. (2022). Exome sequencing of glioblastoma-derived cancer stem cells reveals rare clinically relevant frameshift deletion in MLLT1 gene. Cancer Cell International, 22(1), 9.

de Matos, R. R., Ferreira, G. M., Meyer, C., Marschalek, R., Larghero, P., Ribeiro, R. C., ... & Silva, M. L. M. (2022). KMT2A-MLLT1 and the Novel SEC16A-KMT2A in a Cryptic 3-Way Translocation t (9; 11; 19) Present in an Infant With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 44(3), e719-e722.

Ni, X., Londregan, A. T., Owen, D. R., Knapp, S., & Chaikuad, A. (2021). Structure and inhibitor binding characterization of oncogenic MLLT1 mutants. ACS Chemical Biology, 16(4), 571-578.

Ni, X., Heidenreich, D., Christott, T., Bennett, J., Moustakim, M., Brennan, P. E., ... & Chaikuad, A. (2019). Structural insights into interaction mechanisms of alternative piperazine-urea YEATS domain binders in MLLT1. ACS medicinal chemistry letters, 10(12), 1661-1666.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols